RO 488071
Latest Information Update: 08 Nov 2006
At a glance
- Originator Roche
- Class Antihyperlipidaemics
- Mechanism of Action Cholesterol synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia
Most Recent Events
- 08 Nov 2006 Discontinued - Clinical-Phase-Unknown for Hyperlipidaemia (unspecified route)
- 27 May 1998 New profile
- 27 May 1998 Investigation in Hyperlipidaemia (Unknown route)